semaglutide patent expiry Generic INN entry, pharmaceutical and freedom to operate Off-patent semaglutide in 2026: the

Faujo Nintewoue GF, Tali Nguefak LD, Ngatcha G, Tagni SM, Talla P, Menzy Moungo-Ndjole CM, et al

Methods Study design The SEMPA trial (Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in Patients with Type 2 Diabetes A Randomized Trial) was a 32 week investigator-initiated, randomised, partly placebo-controlled, partly open-label trial, designed to assess the separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and arterial stiffness as two co-primary outcomes

This may induce anesthesiologist-led efforts to delay elective cases until a sufficient washout period, ideally up to 14 days for major surgery

doi:10.1172/JCI112298